Coherus Biosciences
Developer of biosimilar theraputics
Based in CA
🤖
AI Overview
With $1.3M in lobbying spend across 24 quarterly filings, Coherus Biosciences is a significant lobbying presence. Their lobbying covers 2 issue areas. Active from 2018 to 2023.
$1.3M
Total Spend
6
Years Active
1
Firms Hired
2
Lobbyists Deployed
2
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $120K |
| 2019 | $240K |
| 2020 | $240K |
| 2021 | $240K |
| 2022 | $220K |
| 2023 | $200K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Pharmacy
- •Issues related to the development of a healthy biosimilars marketplace in the United States.
- •Executive and Legislative initiatives to allow the biosimilars market place to succeed in the United States.
- •Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the Un
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.